Shares in Translate Bio in huge jump after Sanofi deal news

23 June 2020
sanofi_france_large

Translate Bio (Nasdaq: TBIO), the messenger RNA (mRNA) company, was trading up to 76% higher in pre-market activity on Tuesday.

The US biotech had just announced that it was expanding its existing 2018 collaboration and license agreement with French pharma major Sanofi (Euronext: SAN) to develop mRNA vaccines across all infectious disease areas.

Translate Bio will receive $425 million in an upfront payment and common stock equity investment, and overall is eligible to receive up to $1.9 billion of potential milestone payments, as well as tiered royalties on worldwide sales of developed vaccines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology